Turn Therapeutics Inc. Stock-Based Compensation
Turn Therapeutics Inc. (TTRX) reported Stock-Based Compensation of $700.06 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Turn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $419.23K, a 788.51% increase year-over-year.
- Turn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $280.83K, a 266.63% increase year-over-year.
- Turn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $256.38K, a 578.02% increase year-over-year.
- Turn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $39.08K.
- Turn Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $419.25K, a 18.82% increase from fiscal 2024.
- Turn Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $352.83K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $419.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $700.06K 10-Q · filed 2026-08-12 | $956.44K derived: sum of 3 quarters · filed 2026-08-12 | $995.53K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $280.83K 10-Q · filed 2026-05-11 | $537.21K derived: sum of 2 quarters · filed 2026-05-11 | $576.29K derived: sum of 3 quarters · filed 2026-05-11 | $623.48K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $256.38K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $295.46K derived: sum of 2 quarters · filed 2026-03-31 | $342.65K derived: sum of 3 quarters · filed 2026-08-12 | $419.25K 10-K · filed 2026-03-31 |
| 2025-09-30 | $39.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $86.27K derived: sum of 2 quarters · filed 2026-08-12 | $162.87K 10-Q · filed 2025-11-13 | $200.68K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $47.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $123.78K 10-Q · filed 2026-08-12 | $161.59K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $76.60K 10-Q · filed 2026-05-11 | $114.41K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $37.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $352.83K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $315.02K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |